SUMF2

Across TCGA pan-cancer cohorts, SUMF2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SUMF2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher SUMF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SUMF2 expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

COAD, LUAD, and HNSC are the cancer types where SUMF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	1.000	0.892	.026	42	view →
LUAD	DFS	Tertile	All	0.847	0.973	.003	40	view →
HNSC	OS	Median	II,III,IV	0.599	0.832	.002	24	view →
UCEC	DFS	Median	All	0.946	0.759	.002	14	view →
CCRCC	DFS	Tertile	IV	0.887	0.260	.024	10	view →
PDAC	OS	Median	III,IV	0.783	0.305	.006	9	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SUMF2–COAD (DFS)

Open the COAD breakdown →